Generic Name : Pertuzumab Therapeutic Classification : Monoclonal antibodies ICD Code : Y43.4
International- Perjeta. Why it is prescribed (Indications) :
This medication is a monoclonal antibody, prescribed for HER2-positive breast cancer (which is more aggressive) either alone or with other medications. It stops cancer cell growth. When it is not to be taken (Contraindications): None.
Dosage & When it is to be taken :
IV- The recommended initial dose is 840 mg, followed every 3 weeks thereafter by a dose of 420 mg. How it should be taken :
It comes as a solution for injection to be administered by a healthcare provider into the vein. Warnings and Precautions :
* Caution should be exercised in patients with liver or kidney impairment, during pregnancy and breastfeeding.
* Patient may develop with increased risk of ventricular dysfunction; monitor heart function regularly while taking this medication.
* It may cause harm to fetus when it is administered to pregnant women; consult with your healthcare provider before taking this medication. Side Effects :
Most Common - Diarrhea, hair loss, decrease in white blood cells, stomach upset, fatigue, rash, damage to the nerves.
General - Fatigue, weakness, swelling in the extremities, fever.
Skin- Hair loss, nail disorder, itching, dry skin.
Gastrointestinal - Nausea, vomiting, constipation, mouth ulcer.
Blood - Anemia.
Central Nervous System - Headache, change in taste, dizziness, and sleeplessness.
Musculoskeletal - Muscle pain, joint pain.
Infections - Upper respiratory tract infection, nose inflammation.
Respiratory - Difficulty in breathing.
Metabolic - Decreased appetite.
Eye - Increased tears.
* Avoid excess dosage. Storage Conditions :
Store vials in a refrigerator at 2°C to 8°C.
Comment & Contribute
Ask an Expert